Merck (MRK) announced the start of construction for a $3B, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70B investment beginning in 2025 to expand domestic manufacturing and research and development – not including any future business development transactions in R&D – to drive its long-term growth and strengthen the status of the U.S. as a global leader in biopharmaceutical innovation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- IO Biotech reports expanded Cylembio results
- Merck announces KEYTRUDA, Padcev trial showed improvements in EFS
- Merck, Eisai announce follow-up data on KEYTRUDA plus LENVIMA
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market
- Merck KGaA Joins Price Cut Agreement with Trump to Dodge Tariffs